Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Esperion Therapeutics Inc
0ETCurrent price
1.91 EUR
0 EUR (0.00%)
Last closed
2.23 USD
Company
www.esperion.com
ISIN
US29664W1053
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Frankfurt Exchange
Capitalization
447 392 992 USD
Yield for 12 month
+82.61 %
1Y
3Y
5Y
10Y
15Y
0ET
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.51 USDP/E ratio
–Dividend Yield
–Current Year
+116 334 000 USD
Last Year
+75 475 000 USD
Current Quarter
+51 632 000 USD
Last Quarter
+73 834 000 USD
Current Year
+72 903 000 USD
Last Year
+48 508 000 USD
Current Quarter
+51 632 000 USD
Last Quarter
+58 215 000 USD
Key Figures 0ET
1 year
3 years
5 years
10 years
EBITDA
16 497 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
3.84 %
PEG Ratio
-4.78
Return On Equity TTM
-260.79 %
Wall Street Target Price
7.51 USD
Revenue TTM
295 451 008 USD
Book Value
-1.89 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
52 %
Dividend Yield
–
Gross Profit TTM
-70 419 000 USD
Earnings per share
-0.85 USD
Diluted Eps TTM
-0.85 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-29.37 %
Dividend Analytics 0ET
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0ET
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
11.06.2013
Dividend Date
–
Stock Valuation 0ET
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.7637
Enterprise Value Revenue
1.8944
Price Sales TTM
1.5143
Enterprise Value EBITDA
-3.8634
Price Book MRQ
98.4236
Financials 0ET
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0ET
For 52 weeks
0.96 USD
3.4 USD
50 Day MA
1.91 USD
Shares Short Prior Month
37 467 113
200 Day MA
2.21 USD
Short Ratio
10.64
Shares Short
35 388 048
Short Percent
18.08 %
BeatStart